Valganciclovir for symptomatic congenital cytomegalovirus disease

New England Journal of Medicine

Volumn 372, Issue 10, 2015, Pages 933-943

  Kimberlin, D W ^a   Jester, P M ^a   Sanchez P J ^c   Ahmed, A ^e   Arav Boger, R ^f   Michaels, M G ^g   Ashouri, N ^h   Englund, J A ^k   Estrada, B ^b   Jacobs, R F ^l   Romero, J R ^l   Sood, S K ^m   Whitworth, M S ^d   Abzug, M J ^p   Caserta, M T ⁿ   Fowler, S ^q   Lujan Zilbermann, J ^r   Storch, G A ^s   DeBiasi, R L ^t   Han, J Y ^u   Palmer, A ^v   Weiner, L B ^o   Bocchini, J A ^w   Dennehy, P H ^x   Finn, A ^y   Griffiths, P D ^z   Luck, S ^z   Gutierrez, K ⁱ   Halasa, N ^ab   Homans, J ^j   Shane, A L ^ac   Sharland, M ^aa   Simonsen, K ^ad   Vanchiere, J A ^w   Woods, C R ^ae   Sabo, D L ^g   Aban, I ^a   Kuo, H ^a   James, S H ^a   Prichard, M N ^a   Griffin, J ^a   Giles, D ^a   Acosta, E P ^a   Whitley, R J ^a   more..

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d The Jane and John Justin Neuroscience Center   (United States)

^e CAROLINAS MEDICAL CENTER   (United States)

^f DEPARTMENT OF PATHOLOGY   (United States)

^g CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^h CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

^l UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^m Northwell Health   (United States)

ⁿ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^o SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^p UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^q MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^r UNIVERSITY OF SOUTH FLORIDA   (United States)

^s WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^u UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^v UNIVERSITY OF MISSISSIPPI   (United States)

^w LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^x BROWN UNIVERSITY   (United States)

^y BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^z ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^aa ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^ab VANDERBILT UNIVERSITY   (United States)

^ac EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ad UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^ae University of Louisville School of Medicine   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VALGANCICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR;

AGE DISTRIBUTION; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONGENITAL INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; NEWBORN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; ANALOGS AND DERIVATIVES; AUDIOMETRY; CHEMICALLY INDUCED; CHILD DEVELOPMENT; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CYTOMEGALOVIRUS INFECTIONS; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; EVOKED BRAIN STEM AUDITORY RESPONSE; GESTATIONAL AGE; HEARING LOSS, SENSORINEURAL; VIROLOGY;

ANTIVIRAL AGENTS; AUDIOMETRY; CHILD DEVELOPMENT; CYTOMEGALOVIRUS INFECTIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; GANCICLOVIR; GESTATIONAL AGE; HEARING LOSS, SENSORINEURAL; HUMANS; INFANT, NEWBORN; NEUTROPENIA;

EID: 84924452538     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1404599     Document Type: Article

References (28)

1. Morton CC, Nance WE. Newborn hearing screening- A silent revolution. N Engl J Med 2006;354: 2151-64.
2. Fowler KB, McCollister FP, Dahle AJ, Boppana S, Britt WJ, Pass RF. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 1997;130: 624-30.
3. Fowler KB, Dahle AJ, Boppana SB, Pass RF. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed? J Pediatr 1999;135: 60-4.
4. Fowler KB, Boppana SB. Congenital cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol 2006;35: 226-31.
5. Elek SD, Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1974;1: 1-5.
6. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007;17: 253-76.
7. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007;17: 355-63.
8. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev 2013;26: 86-102.
9. Williamson WD, Desmond MM, LaFevers N, Taber LH, Catlin FI, Weaver TG. Symptomatic congenital cytomegalovirus: disorders of language, learning, and hearing. Am J Dis Child 1982;136: 902-5.
10. Dahle AJ, Fowler KB, Wright JD, Boppana SB, Britt WJ, Pass RF. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J Am Acad Audiol 2000;11: 283-90.
11. Boppana SB, Ross SA, Fowler KB. Congenital cytomegalovirus infection: clinical outcome. Clin Infect Dis 2013;57: Suppl 4: S178-S181.
12. Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin Virol 2008;41: 57-62.
13. Kimberlin DW, Lin CY, Sánchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003;143: 16-25.
14. Oliver SE, Cloud GA, Sánchez PJ, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involv- ing the central nervous system. J Clin Virol 2009;46: Suppl 4: S22-S26.
15. Kimberlin DW, Acosta EP, Sánchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008;197: 836-45.
16. Cytomegalovirus infection. In: Pickering LK, Baker CJ, Long SS, Kimberlin DW, eds. Red Book: 2012 report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2012: 300-5.
17. Bayley N. Bayley Scales of Infant Development technical manual. 3rd ed. San Antonio, TX: Harcourt Assessment, 2006.
18. Boppana SB, Ross SA, Novak Z, et al. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA 2010;303: 1375-82.
19. National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events (DAIDS AE Grading Table). 2004 (http://rsc.tech-res.com/Document/safetyand pharmacovigilance/Table-for-Grading-Severity-of-Adult-Pediatric-Adverse -Events.pdf).
20. Meine Jansen CF, Toet MC, Rademaker CM, Ververs TF, Gerards LJ, van Loon AM. Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir. J Perinat Med 2005;33: 364-6.
21. Müller A, Eis-Hübinger AM, Brandhorst G, Heep A, Bartmann P, Franz AR. Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant. J Perinatol 2008;28: 74-6.
22. Shoji K, Ito N, Ito Y, et al. Is a 6-week course of ganciclovir therapy effective for chorioretinitis in infants with congenital cytomegalovirus infection? J Pediatr 2010; 157: 331-3.
23. Kashiwagi Y, Kawashima H, Nakajima J, et al. Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection. J Infect Chemother 2011; 17: 538-40.
24. Yilmaz Çiftdogan D, Vardar F. Effect on hearing of oral valganciclovir for asymptomatic congenital cytomegalovirus infection. J Trop Pediatr 2011;57: 132-4.
25. Tanaka-Kitajima N, Sugaya N, Futatani T, et al. Ganciclovir therapy for congenital cytomegalovirus infection in six infants. Pediatr Infect Dis J 2005;24: 782-5.
26. Lombardi G, Garofoli F, Villani P, et al. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 2009;28: 1465-70.
27. Amir J, Wolf DG, Levy I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr 2010;169: 1061-7.
28. Roche Pharmaceuticals. Valganciclovir package insert (http://www.accessdata.fda.gov/drugsatfda-docs/label/2001/21304lbl.pdf).